InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.90% | -18.95% | 15.19% | 10.38% | 111.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.90% | -18.95% | 15.19% | 10.38% | 111.22% |
| Cost of Revenue | -25.33% | 25.54% | -11.21% | 64.24% | 101.67% |
| Gross Profit | -20.41% | -22.54% | 18.56% | 2.80% | 112.31% |
| SG&A Expenses | -0.79% | -20.14% | -5.05% | 6.97% | 58.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.80% | -18.52% | -8.43% | 9.21% | 56.40% |
| Operating Income | -446.02% | -25.56% | 140.35% | -2.80% | 129.19% |
| Income Before Tax | -303.99% | -107.60% | 102.70% | 100.52% | 138.42% |
| Income Tax Expenses | -47.37% | -56.90% | 11.97% | -76.17% | -- |
| Earnings from Continuing Operations | -681.69% | -132.95% | 84.25% | 93.97% | 115.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 48.61% | 55.57% | -12.78% | 24.14% | -187.00% |
| Net Income | -571.38% | -275.07% | 67.06% | 87.09% | 85.69% |
| EBIT | -446.02% | -25.56% | 140.35% | -2.80% | 129.19% |
| EBITDA | -434.35% | -25.28% | 141.51% | -3.05% | 130.16% |
| EPS Basic | -546.94% | -268.21% | 69.39% | 87.99% | 86.88% |
| Normalized Basic EPS | -690.38% | -198.91% | 71.29% | 86.78% | 90.76% |
| EPS Diluted | -546.94% | -268.21% | 69.39% | 87.99% | 86.88% |
| Normalized Diluted EPS | -690.38% | -198.91% | 71.29% | 86.78% | 90.76% |
| Average Basic Shares Outstanding | 3.83% | 4.12% | 7.60% | 7.47% | 9.04% |
| Average Diluted Shares Outstanding | 3.83% | 4.12% | 7.60% | 7.47% | 9.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |